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In eThekwini, South Africa, the production of agricultural fertilizers from human urine collected from
urine-diverting dry toilets is being evaluated at a municipality scale as a way to help ﬁnance a decen-
tralized, dry sanitation system. The present study aimed to assess a range of human and environmental
health hazards in source-separated urine, which was presumed to be contaminated with feces, by
evaluating the presence of human pathogens, pharmaceuticals, and an antibiotic resistance gene.
Composite urine samples from households enrolled in a urine collection trial were obtained from urine
storage tanks installed in three regions of eThekwini. Polymerase chain reaction (PCR) assays targeted 9
viral and 10 bacterial human pathogens transmitted by the fecaleoral route. The most frequently
detected viral pathogens were JC polyomavirus, rotavirus, and human adenovirus in 100%, 34% and 31%
of samples, respectively. Aeromonas spp. and Shigella spp. were frequently detected gram negative
bacteria, in 94% and 61% of samples, respectively. The gram positive bacterium, Clostridium perfringens,
which is known to survive for extended times in urine, was found in 72% of samples. A screening of 41
trace organic compounds in the urine facilitated selection of 12 priority pharmaceuticals for further
evaluation. The antibiotics sulfamethoxazole and trimethoprim, which are frequently prescribed as
prophylaxis for HIV-positive patients, were detected in 95% and 85% of samples, reaching maximum
concentrations of 6800 mg/L and 1280 mg/L, respectively. The antiretroviral drug emtricitabine was also
detected in 40% of urine samples. A sulfonamide antibiotic resistance gene (sul1) was detected in 100% of
urine samples. By coupling analysis of pathogens and pharmaceuticals in geographically dispersed
samples in eThekwini, this study reveals a range of human and environmental health hazards in urine
intended for fertilizer production. Collection of urine offers the beneﬁt of sequestering contaminants
from environmental release and allows for targeted treatment of potential health hazards prior to
agricultural application. The efﬁcacy of pathogen and pharmaceutical inactivation, transformation or
removal during urine nutrient recovery processes is thus brieﬂy reviewed.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Decentralized sanitation technologies that separate human
urine from feces at the toilet user interface have been implemented
in low-, middle- and high-income countries, though primarily at
pilot scales. Source-separation of urine has the advantage over
traditional toilets of sequestering nutrients primarily excreted in
urine, namely nitrogen, potassium, and phosphorus, whilehel).enhancing the dehydration of separately stored feces in dry toilets.
Collected urine can be used directly as a fertilizer in agriculture
after a period of storage or processed into concentrated powder or
liquid products. The use or sale of urine-derived fertilizers could
offset the purchase of costly synthetic fertilizers or generate a
source of revenue for sanitation service providers. Such a sanitation
system would also reduce nutrient loads to treatment facilities or
other urine discharge locations (Larsen et al., 2013).
The eThekwini Water and Sanitation (EWS) municipality in the
KwaZulu-Natal province of South Africa serves the greater eThek-
wini region including Durban. EWS installed over 80,000 urine
diverting dry toilets (UDDTs) in historically underserved rural and
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scale-up of urine collection and use. Currently in this system,
source-separated urine is diverted to soak pits, and feces are
collected in vaults for drying. EWS would like to incorporate
nutrient recovery from urine into the system. The VUNA (Valor-
isation of Urine Nutrients in Africa) project is designing, testing and
optimizing urine collection and nutrient recovery technologies to
produce a commercially viable fertilizer. Pilot-scale technologies
have been developed to produce a solid phosphate-based fertilizer
(struvite) as well as a concentrated liquid fertilizer via biological
nitriﬁcation and distillation (Udert et al., 2015). Urine-derived fer-
tilizers, and their production processes, need to be safewith respect
to environmental and public health concerns. This study thus aims
to identify potential human and environmental health hazards in
source-separated urine, targeting microbial and chemical contam-
inants. The ultimate goal is to promote the hygienic handling of
urine and to design fertilizer production technologies that allow for
its safe end use as a fertilizer.
The most pressing human health concerns associated with
source-separated urine stem from the presence of human patho-
gens.While enteric pathogens are primarily excreted in feces rather
than urine, the cross-contamination of source-separated urine with
feces is well established (Sch€onning et al., 2002). Diseases trans-
mitted by the fecaleoral route are therefore relevant in the design
of urine treatment and recycling systems. Pathogen reduction can
be partially achieved through storage, which allows inactivation by
heat or ammonia (Decrey et al., 2015; Nordin et al., 2013). The
World Health Organization (WHO) recommends storage for >6
months at >20 C to achieve sufﬁcient pathogen inactivation in
urine intended for agricultural use for unprocessed food crops
(WHO, 2006). While feasible in rural areas with ample space, this
storage time can be prohibitive for urine collection at scale in dense
urban environments due to storage volume requirements. Long
term storage can also cause odor problems and lead to loss of
recoverable nutrients by ammonia volatilization. These challenges
highlight the need for alternative urine treatment technologies.
Urine-derived fertilizers can be produced after short-term urine
storage and provide a treatment beneﬁt. However, implementation
of this strategy necessitates investigation of the fate of locally
relevant pathogens in the fertilizer production processes.
While pathogens are primarily human health hazards, the pri-
mary concerns for the presence of trace organic compounds
(TrOCs) in the environment stem from their potential ecosystem
health hazards (Kolpin et al., 2002). A meta-analysis of 212 phar-
maceuticals revealed that an average of 64% of the consumed mass
is excreted in urine (Lienert et al., 2007). The use and excretion of
antiretroviral (ARV) drugs may be of particular interest in South
Africa where HIV prevalence is high, particularly in the KwaZulu-
Natal province (16.9% of the population in 2012; Shisana et al.,
2014). South Africa has rolled out the largest ARV treatment pro-
gram in the world e in 2012, 31.2% of eligible people living with
human immunodeﬁciency virus (HIV) or Acquired Immune Deﬁ-
ciency Syndrome (AIDS) had been exposed to ARV treatment
(Shisana et al., 2014). While the beneﬁts of this program are clearly
demonstrated through the reduction of AIDS deaths in the country,
antiviral pharmaceuticals were predicted to be amongst the most
hazardous therapeutic drug classes for several ecotoxicological
end-points (Sanderson et al., 2004). Commonly prescribed anti-
bacterial compounds with high excretion rates may also be prev-
alent in source-separated urine. Sulfamethoxazole and
trimethoprim, for example, are frequently prescribed together as a
broad-spectrum prophylaxis against bacterial pathogens and pro-
tozoa for HIV-positive patients (Zachariah et al., 2007). One po-
tential human health consequence of such widespread use of
antibiotics for infectious disease therapy is the acceleratedpropagation of antibiotic resistance, especially in low-income
countries (Okeke et al., 2005).
The objective of this study was to evaluate the presence of
pathogenic organisms that are causative agents of diarrheal disease
as well as pharmaceuticals in source-separated urine collected
from throughout eThekwini. Based on a review of enteric patho-
gens present in South Africa, polymerase chain reaction (PCR) as-
says targeting 9 viral and 10 bacterial pathogens transmitted by the
fecaleoral route were selected for a screening of human pathogens
in the collected urine. An initial screening of 41 TrOCs in the urine
facilitated selection of 12 priority pharmaceuticals for further
quantitative evaluation. The presence of a sulfonamide antibiotic
resistance gene (ARG) in bacteria from urine was also evaluated. By
coupling analysis of pathogens and pharmaceuticals, this study
seeks to identify a range of priority human and environmental
health risk determinants in urine that is intended for fertilizer
production and agricultural applications.
2. Materials and methods
2.1. Sampling
Samples were collected at four different times between 2010
and 2013. Samples from 2010 to 2011 were used for TrOC method
validation and to select priority compounds for further monitoring.
These initial urine samples were collected from two UDDTs on 10
November 2010, and four composite samples consisting of urine
from 29 UDDTs were obtained between 28 April and 25 May 2011.
The composite samples were prepared by adding urine collected
daily over one week to a 1500 L black polyethylene tank. At the end
of the week, the tank was stirred and sampled into triplicate 50 ml
centrifuge tubes. The tank was then emptied in preparation for the
subsequent composite sample.
Samples collected in 2012 and 2013 were geographically
distributed in the EWS service area. From December 2012 to May
2013, nine urine storage tanks of 1000e1500 L capacity were
temporarily installed in three distinct regions of the EWS service
area in peri-urban Durban as part of an economic study on the
collection of urine using incentives (Tilley, 2015). Three urine tanks
were installed per region, and each tank was accessible for urine
deposits by approximately 90e150 nearby households that were
provided with urine collection jerry cans. Tanks received deposits
of urine carried by individuals from their homes to the tanks during
opening hours one day per week. Urine tanks were emptied by the
municipality when full. The nine storage tanks were sampled on
December 19, 2012 and subsequently on several days from April
12e29, 2013 for combined TrOC and microbiological assessments.
In December, two additional urine tanks (UT) located at the Uni-
versity of KwaZulu-Natal (UKZN) were also sampled. The study
plan was approved by the UKZN Biomedical Research Ethics Com-
mittee (BE147/13). Speciﬁc locations of the sampling sites are
omitted as stipulated in the project protocol.
2.2. Chemical and physical urine characteristics
The urine pH, temperature, conductivity, total ammonia and
orthophosphate concentrations were measured as described in the
Supporting information.
2.3. Analytes
2.3.1. Bacteria
The presence of bacterial pathogens wasmonitored by detection
of bacterial DNA. Bacteria targets in this study were: Clostridium
perfringens, Yersinia enterocolitica, Escherichia coli O157:H7,
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(A. salmonicida, A. sobria, A bivalvium, A. hydrophila), Vibrio spp.
(V. cholera, V parahamolyticus, and V. vulniﬁcus), C. difﬁcile toxin B,
Salmonella spp. (Salmonella bongori and Salmonella enterica),
Shigella spp. (Shigella ﬂexneri, Shigella boydii, Shigella sonnei and
Shigella dysenteriae) and Campylobacter spp. (C. jejuni and C. coli).
Multiplex end-point PCR was conducted using two bacterial See-
gene ACE Diarrheal detection kits (BÜHLMANN Laboratories AG,
Sch€onenbuch, Switzerland). Details of sample processing pro-
cedures are available in the Supporting information. Each of the
urine tanks were also evaluated for total viable heterotrophic
bacteria (April 2013) as an indicator of the total bacteria concen-
trations in source-separated urine. Oneml of each of three dilutions
of sampled urine (at least 100-fold dilution in phosphate buffered
saline, 5 mM PO4, 10 mM NaCl, pH 7.4) from each urine tank was
aliquoted on a 3M Petriﬁlm dryplate (3M, St. Paul, MN, USA) and
handled as per manufacturer instructions. Plates were incubated
for 48 h at 35 C prior to enumeration, and results are presented as
colony forming units per ml urine sampled (CFU/ml).
2.3.2. Viruses
The presence of viruses was monitored by detection of viral RNA
or DNA. The viral targets were human adenovirus (HAdV), rotavirus
(RoV), norovirus (NoV) GI and GII, human astrovirus (HAstV), en-
teroviruses (EV), hepatitis A Virus (HAV) and JC Polyomavirus
(JCPyV). While not typically associated with fecal contamination,
JCPyV was included herein because it has been detected consis-
tently inwastewater worldwide (Boﬁll-Mas et al., 2000). Unlike the
other viruses evaluated, JCPyV is excreted indeﬁnitely in the urine
of healthy individuals following infection. As such, this virus was
expected to be ubiquitously present in urine, and served as an in-
ternal process control for virus extraction and detection. Bacterio-
phage MS2 (DSMZ 13767) was used for optimization of the nucleic
acid extraction procedure and PCR method. HAdV, RoV, NoV GI and
GII, and HAstV were analyzed by viral Seegene ACE Diarrheal
detection kits (BÜHLMANN Laboratories AG, Sch€onenbuch,
Switzerland), which included positive controls. EV and MS2 were
analyzed by one-step reverse-transcriptase (RT)-PCR with SYBR
Green using a Rotor-Gene 3000 thermocycler. HAV and JCPyV were
analyzed by RT-PCR with selective Taqman® probes. Further
method details are available in the Supporting information.
2.3.3. Trace organics
A method initially developed to analyze pharmaceuticals in
hospital wastewater (Kovalova et al., 2012) was validated on 2010
and 2011 samples. Samples were screened for a group of 41 TrOCs
(see Supporting information) using liquid chromatography tandem
mass spectrometry (LC-MS/MS). A group of 12 priority compounds
were selected for further monitoring in the 2012 and 2013 sam-
pling campaign. Concentrations are reported as averages with 95%
conﬁdence intervals (CI) unless otherwise noted. Details of the
analytical method as well as the process for selecting priority
pharmaceutical analytes are available in the Supporting
information. Methods applied for the analysis of the sulphona-
mide antibiotic resistance gene sul1 are described in the Supporting
information.
3. Results
3.1. Urine tank conditions
Characteristics of urine in the storage tanks during 2012 and
2013 sampling campaigns are presented in Table 1. The average
temperature for all urine tank samples in December 2012 was
25.9 ± 0.7 C, ranging from 24.8 to 34.3 C at the time of sampling,and the pH was 8.72 ± 0.10. The average temperature for all tank
samples in April 2013was 20.4 ± 2.0 C, ranging from 15.5 to 27.1 C
at the time of sampling, with pH 8.90 ± 0.09. Average ammonia
measured in urine tanks was 2240 ± 1180 mg/L NH4eN (range of
400e8550mg/L NH4eN) and average phosphatewas 240± 20mg/l
PO4eP (range of 170e290 mg/l PO4eP).
3.2. Pathogen detection in source-separated urine
The detection frequencies of pathogenic bacteria and viruses in
the urine storage tanks during the 2012 and 2013 sampling cam-
paigns are presented in Table 2. Up to six pathogens were detected
in a single urine sample.
3.2.1. Bacteria occurrence
The following bacteria were detected in at least two urine tank
samples: C. perfringens, Y. enterocolitica, E. coli 0157:H7,
verocytotoxin-producing E. coli (VTEC), Aeromonas. spp., Vibrio spp.,
and Shigella spp. At least one diarrheal bacterium species was
detected in each of the 18 samples (100%), and an average of three
bacteria species were detected in each sample. Two samples con-
tained ﬁve bacteria species each, the maximum number of diar-
rheal bacteria species detected in a single sample. Region 2 had the
most total detects followed by Region 3 and Region 1 (Table 2). The
highest frequency detected bacteria were Aeromonas spp. (94%);
C. perfringens (72%); and Shigella spp. (61%). Three of the bacteria
were not detected in any samples: C. difﬁcile, Salmonella spp., and
Campylobacter spp. Heterotrophic plate counts ranged from 1 105
to 7  106 CFU/ml across all urine tanks sampled, with an average
concentration of 2  106 CFU/ml.
3.2.2. Virus occurrence
The following viruses were detected in at least one urine sample
from Durban: JC polyomavirus, human adenovirus, rotavirus, hep-
atitis A virus, and norovirus GII. Three to ﬁve virus species were
detected in each of the sampling regions, and up to three virus
species were detected in a single sample. The three most frequently
detected viruses were JCPyV, HAdV and RoV detected in 100%, 34%
and 31% of samples, respectively. In the present study, NoV GII was
detected in only one sample, which was collected in April 2013.
HAstV and NoV GI were not detected.
3.3. Pharmaceuticals in source-separated urine
Concentrations of pharmaceuticals from the priority list for
samples taken from urine storage tanks in December 2012 and
April 2013 are shown by region in Table 2 and discussed below. Up
to 10 of 12 pharmaceuticals assessedwere detected in a single urine
sample. Results from the 2010 and 2011 screening are available in
the Supporting information.
3.3.1. Antibacterial detection
The antibacterial pharmaceuticals tested in this study were:
sulfamethoxazole (SMX), trimethoprim (TMP), and clarithromycin.
N4-acetylsulfamethoxazole (N4-AcSMX), a human metabolite of
SMX, was also tested. SMX and its conjugate N4-AcSMX as well as
TMP were frequently detected at high concentrations. SMX, N4-
AcSMX and TMP were detected in 95%, 90% and 85% of samples,
respectively, with concentrations in urine reaching 6800, 3500 and
1300 mg/L, respectively. In contrast, clarithromycin was detected in
only 20% of samples and at relatively lower concentrations in this
study (17 ± 29 mg/L). The sum of SMX and N4-AcSMX (
P
SMX)
concentrations varied widely from less than 2 mg/L to 8500 mg/L,
with an average of 2700 ± 1100 mg/L. A weak correlation was
observed between TMP concentrations and
P
SMX (R2 ¼ 0.34),
Table 1
Characteristics of urine in storage tanks.
Region Sample collection Ammonia (mg/L NH4eN)
avg. ±95% CI (range, n)
Conductivity (mS/cm)
avg. ±95% CI (range, n)
Temperature (C)a
avg. ±95% CI (range, n)
pH avg. ±95% CI (range, n)
1 December 2012 e 30.3 ± 3.4 (25e34.3, 6) 27.6 ± 0.3 (27.2e28.1, 6) 8.65 ± 0.06 (8.58e8.75, 6)
April 2013 1500 ± 530 (400e2100, 6) e 20.3 ± 0.5 (19.8e20.8, 3) 9.02 ± 0.08 (8.95e9.08, 3)
2 December 2012 e 25.7 ± 0.7 (24.8e26.8, 6) 24.5 ± 0.5 (23.7e24.9, 6) 8.88 ± 0.04 (8.81e8.9, 6)
April 2013 2250 ± 640 (1600e2650, 3) e 19.2 ± 3.8 (15.5e27.1, 6) 8.91 ± 0.13 (8.68e9.08, 6)
3 December 2012 e 27.5 ± 2.3 (25.5e31.3, 6) 25.6 ± 1.0 (24.1e26.5, 6) 8.63 ± 0.24 (8.26e8.90, 6)
April 2013 3650 ± 4820 (800e8550, 3) e 22.8 ± 1.6 (21.3e24.2, 3) 8.75 ± 0.15 (8.60e8.86, 3)
a In Durban, the average low temperature is 20 C in December and 18 C in April; the average high temperature is 28 C in December and 27 C in April.
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P
SMXwas found in very high concentrations, TMP
was also typically measured at elevated concentrations.
3.3.2. Antiviral detection
Among the four analyzed antivirals, only emtricitabine and ri-
tonavir were detected, in 40% and 70% of samples, respectively. The
concentration of emtricitabine averaged to 100 ± 97 mg/L but was
highly variable among storage tanks with a maximum concentra-
tion of more than 900 mg/L. Ritonavir concentrations were typically
low, with an average concentration of 1.5 ± 0.5 mg/L and a
maximum concentration of 5 mg/L.
3.3.3. Other pharmaceuticals
The anti-inﬂammatory drug diclofenac was detected consis-
tently in 100% of the samples, though typically at lowTable 2
Detection of pathogens, pharmaceuticals, and antibiotic resistance genes in source-sepa
Region 1 Region 2
Dec. '12 Apr. '13 Dec. '12 Apr. '13
Virus Detection frequency Detection frequency
JC polyomavirus 3 6 3 6
Adenovirus 2 2 1 0
Rotavirus 3 0 3 1
Hepatitis A virus 0 0 0 1
Norovirus GII 0 0 0 1
Astrovirus 0 0 0 0
Echovirus 0 0 0 0
Enterovirus 0 0 0 0
Norovirus GI 0 0 0 0
Bacterium Detection frequency Detection frequency
Aeromonas spp. e 5 e 6
C. perfringens e 2 e 6
Shigella spp. e 2 e 5
Vibrio spp. e 2 e 2
Y. enterocolitica e 0 e 0
E.coli O157:H7 e 1 e 1
VTEC e 0 e 2
Campylobacter spp. e 0 e 0
C. difﬁcile toxin B e 0 e 0
Salmonella spp. e 0 e 0
Pharmaceutical Concentration range (mg/L) Concentration range (mg
Diclofenac 3.2e72 20e62 1.6e45 16e44
Sulfamethoxazole <2e300 320e5200 800e5000 1000e680
N4 Acetyl-SMX <1e560 280e720 60e3500 9.6e280
Trimethoprim <2e3.6 22e380 4.3e56 260e1300
Hydrochlorothiazide <3e19 52e94 17e120 18e64
Atenolol acid 4.2e100 <4e100 <4e11 <4
Ritonavir <1e2.8 <1e1.5 <1e1.7 <1e1.4
Atenolol <1e2.9 <1e300 <1 <1
Emtricitabine <6 <6 <6e920 <6e240
Clarithromycin <1 <1 <1e1.1 <1
Atazanavir <2.5 <2.5 <2.5 <2.5
Darunavir <1 <1 <1 <1
Antibiotic resistance gene Detection frequency Detection frequency
sul1 e 6 e 6
a UT refers to the two urine collection tanks at the University of KwaZuluNatal (UKZNconcentrations (30 ± 10 mg/L; max¼ 72 mg/L). Hydrochlorothiazide,
a diuretic drug often prescribed to treat high blood pressure,
measured on average 42 ± 18 mg/L andwas found in 80% of samples.
The beta-blocker atenolol and its metabolite atenolol acid were
detected in 55% and 75% of samples, respectively, with average
concentrations of 31 ± 33 and 98 ± 110 mg/L. Atenolol acid is a
human metabolite of both atenolol and metoprolol, neither of
which were detected in the initial 2010 and 2011 screening.
3.4. Antibiotic resistance
The sul1 antibiotic resistance gene was present in 100% of bac-
terial extracts (n ¼ 18) and not detected in the two ﬁeld blanks
analyzed. A two-tailed pairwise t-test indicates that duplicate an-
alyses of the same samples were not signiﬁcantly different (p > 0.3).rated urine.
Region 3 UTa All samples
Dec. '12 Apr. '13 Dec. '12
Detection frequency Det. freq. Freq. % (n ¼ 29)
3 6 2 100%
2 3 0 34%
0 0 2 31%
0 1 0 7%
0 0 0 3%
0 0 0 0%
0 0 0 0%
0 0 0 0%
0 0 0 0%
Detection frequency Freq. % (n ¼ 18)
e 6 e 94%
e 5 e 72%
e 4 e 61%
e 0 e 22%
e 2 e 11%
e 0 e 11%
e 0 e 11%
e 0 e 0%
e 0 e 0%
e 0 e 0%
/L) Concentration range (mg/L) Conc. range (mg/L) Freq. % >LOQ (n ¼ 20)
13e56 16e44 27e30 100%
0 560e4800 1600e6400 5e12 95%
8e520 34e174 <1e2 90%
<2e300 100e440 <2 85%
20e134 52e94 <3 80%
8.0e1100 20e98 130e175 75%
1.9e4.6 <1e1.0 2.8 70%
1.2e4.3 20e184 26e29 55%
<6e16 <6e380 26e120 40%
<1 4.4e300 <1 20%
<2.5 <2.5 <2.5 0%
<1 <1 <1 0%
Detection frequency Freq. % (n ¼ 18)
e 6 e 100%
).
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reaction); one of these was excluded as an outlier because it was
several orders of magnitude higher in concentration than replicate
analyses of the sample using the same DNA extraction method
(Method A, see SI), as well as a different extractionmethod (Method
B, see SI). The number of sul1 genome copies detected per ml of
urine sample ranged from 1  108 to 4  1010.
4. Discussion
4.1. Pathogens in source-separated urine and potential health risks
The present study is the ﬁrst of its kind to assess a broad di-
versity of fecal pathogens in source-separated urine. The urine
storage tanks represent a composite of urine from potentially
hundreds of individuals. Any urine handled downstream of this set-
up is likely to contain a mixture of pathogens originating from fecal
contamination. This assumption is corroborated by our ﬁndings
that demonstrate the ubiquitous presence of a wide spectrum of
fecal pathogens in source-separated urine in Durban. The pathogen
load and diversity will depend on the extent of fecal contamination
of the urine, which in turn depends on the toilet user interface
design, usage and maintenance patterns, and disposal processes, in
addition to local cultural practices. For example, whether or not
children use the UDDTs, especially during an active gastrointestinal
infection, will inﬂuence the pathogen proﬁle of the collected waste.
The detection of rotavirus, a common infection in children, in-
dicates that children likely use the UDDTs in eThekwini.
The results presented here are based on presence of the path-
ogen DNA or RNA measured by PCR, and thus do not yield data on
the infectivity of detected pathogens. However, the application of
PCR to identify pathogens in this study is a conservative approach
for the identiﬁcation of potential health hazards in urine by, for
example, addressing the well-known issue of viable but non-
culturable pathogens. A safe assumption for the human patho-
gens detected is that they are infective in fresh feces and therefore
also in freshly contaminated urine. Additionally, pathogen moni-
toring by PCR avoids exclusion of pathogens that were inactivated
at the time of sampling but may pose a health risk to individuals in
contact with the material prior to inactivation. Finally, several
studies have evaluated the inactivation of organisms in source-
separated urine, conﬁrming that some bacteria and viruses may
remain infective in stored urine for months (H€oglund et al., 1998;
Vinneras et al., 2008). It is thus reasonable to assume that the
detected pathogens were at least in part infective, and thus
constitute a potential health risk. A health-risk assessment would
beneﬁt from a culture-based analysis of human pathogens to assess
the viable and culturable status of detected organisms relative to
their total abundance at important exposure points in the urine
collection and handling chain.
When considering the health risks of using source-separated
urine for fertilizer, viruses are of particular relevance due to their
low infective dose and resistance to inactivation in stored urine
(H€oglund et al., 2002a). Each of the viruses detected in this study
have been identiﬁed in various human and environmental matrices
in South Africa. Notably, rotavirus was themost frequently detected
virus in a 2008 survey of fecal specimens from patients with
gastroenteritis in the Pretoria region, followed by adenovirus and
norovirus (Mans et al., 2010). Rotavirus may pose a risk in agri-
cultural applications of urine (H€oglund et al., 2002b) and continues
to be a major contributor to childhood diarrheal disease in South
Africa, though the beneﬁts of a vaccine implemented in 2009 are
beginning to be demonstrated (Seheri et al., 2012). In contrast to
RoV, JCPyV is not expected to increase the public health concerns of
urine collection and agricultural application, though it wasuniversally detected in the samples. JCPyV already infects most
people asymptomatically during childhood, though its pathoge-
nicity emerges in HIV-infected individuals (Major et al., 1992). This
consideration demonstrates the importance of considering the risk
factors of each viral target, in addition to evaluating virus preva-
lence, to assess its relative importance to public health.
Several other viruses that are prevalent in South Africa and
transmitted by the fecaleoral route were not detected in the pre-
sent study. These include enterovirus (Ehlers et al., 2005) and
HAstV (Mans et al., 2010; Taylor et al., 1997). The prevalence of
these viruses could be low, as was the case for HAstV in South Af-
rican patients with gastroenteritis (Taylor et al., 1997), yielding
concentrations below the detection limit. Alternatively, limited
detection could be a result of degradation of the viral genome, an
inactivating process expected for single stranded (ss)RNA viruses in
stored urine (Decrey et al., 2015). ssRNA viruses are less stable than
DNA viruses and double-stranded (ds)RNA viruses, which are ex-
pected to retain their infectivity and genome integrity in urine over
long periods of time (Decrey, 2015). Correspondingly, the three
most frequently detected viruses in this study (JCPyV, HAdV and
RoV) are dsDNA or dsRNA viruses. In contrast, even ssRNA viruses
with high seroprevalence in South Africa, including HAV and NoV
GII (Mans et al., 2010), were detected less frequently. Their limited
detection in the present study may be indicative of genome
degradation during urine storage.
Similar to viral pathogens, the bacterial pathogen targets
assessed in this study have each been detected in various human
and environmental matrices collected in South Africa. For example,
Shigella spp. was commonly identiﬁed in drinking water consumed
by individuals with HIV/AIDS in rural households (Samie et al.,
2012) and may contribute to the chronic diarrhea commonly
experienced by HIV/AIDS patients (Obi and Bessong, 2002). The
etiological agent of cholera, V. cholerae, which was also detected in
our samples, has been regarded as endemic in South Africa and is a
common cause of illness and death in the country (Momba et al.,
2010). While not detected in this study, Campylobacter spp. and
Salmonella spp., along with other diarrhea-causing bacterial path-
ogens, are known to circulate in South Africa (Obi and Bessong,
2002). These results illustrate that while country-speciﬁc preva-
lence studies are useful to identify a range of potential pathogen
hazards, the local relevance of speciﬁc pathogens varies greatly.
In addition to yielding an overview of the health status of the
sample population at the time of measurement, the results indicate
potentially problematic levels of fecal contamination in terms of
health risk to humans during downstream handling and use of the
urine. The actual health risk to humans from this diversity of
pathogens will depend on the inﬂuent composition, pathogen
inactivation rates as well as human exposure routes during urine
handling and processing, which requires further evaluation. JCPyV,
which is excreted in urine, may be useful as an indicator for
tracking the fate of pathogens in source-separated urine or as a
treatment process indicator for viruses because of its consistent
detection. JCPyV has been proposed as a sewage indicator organism
due to its high excretion titer, frequent detection in urban sewage,
stability, and absence of animal host (Boﬁll-Mas et al., 2000).
4.2. Pharmaceutical excretion in urine and potential health risks
Little public information is available concerning speciﬁc phar-
maceutical usage in South Africa, rendering estimation of con-
sumption, and excreted concentrations, difﬁcult. Therefore, average
measured urine concentrations in South Africa were compared to
predicted urine concentrations using pharmaceutical consumption
data from the USA, France, Germany and Switzerland in order to
identify outliers (Table 3). For example, low to no detection of the
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study region, contrary to high-income countries (Michael et al.,
2013). Similarly, concentrations of the diuretic, hydrochlorothia-
zide, were relatively low in eThekwini. However, averagemeasured
concentrations of SMX and TMP in urine were elevated as
compared to predicted concentrations. Concentrations of SMX in
particular were markedly high, more than an order of magnitude
above the range predicted.
In addition to being widely used for the treatment of bacterial
infections, SMX and TMP are frequently prescribed as prophylaxis
to prevent opportunistic infections in patients with compromised
immune systems (e.g., for HIV-positive individuals) (Madhi et al.,
2002). In a preventative approach, patients receive such pharma-
ceuticals regularly over an extended period of time, in contrast to
targeted antibiotic treatment for acute infections. If 4e11% of all
HIV infected persons in the KwaZulu-Natal province were taking
SMX prophylactic (see SI for estimation), this could explain the
observed concentrations of SMX. Therefore, the surprisingly high
SMX concentrations detected are reasonable considering the high
prevalence of HIV-positive people in eThekwini. Additionally, SMX
and TMP prescriptions are often administered together as co-
trimoxazole in a 5:1 ratio. Because N4-AcSMX is a metabolite of
SMX produced in the human body and deconjugates to SMX under
environmental conditions (G€obel et al., 2005), the sum of SMX and
N4-AcSMX was expected to correlate with TMP. Correspondingly,
TMP was usually found in high concentrations when
P
SMX also
occurred in high concentrations, though this prescription ratio was
not preserved in the samples.
In addition to widespread use of antibacterial pharmaceuticals
in South Africa, nationally, just over 2.0 of 6.4 million estimated
people living with HIV in 2012 received anti-retroviral treatment
(Shisana et al., 2014). Of four ARV pharmaceuticals tested, emtri-
citabine and ritonavir were detected. Target antivirals detected at
low concentrations or not detected in storage tanks may reﬂect the
low consumption and/or low excretion rates of those compounds.
Emtricitabine exhibits a urine excretion rate of 75%, whereas less
than 8% of consumed atazanavir, darunavir, and ritonavir are
excreted in urine (Table 3). Therefore, low concentrations or lack of
detection of antivirals other than emtricitabine in the urine is not
necessarily indicative of their low consumption. The presence of
feces in urine may also have contributed to the observed ritonavir,
as 41% of the consumed drug is excreted in feces. Antivirals notTable 3
Predicted and measured pharmaceutical concentrations in 2012 and 2013 urine samples,
urine as a fertilizer.
Compounds Usage Excr
rate
Atazanavir Antiviral 6
Atenolol Beta-blocker 37
Atenolol acid (Human) metabolite of atenolol and metoprolol NDd
Clarithromycin Macrolide antibacterial 25
Darunavir Antiviral 7.7
Diclofenac Analgesic: antiinﬂammaotry/antirheumatic 1
Emtricitabine Antiviral 75
Hydrochlorothiazide Diuretic 82
N4 Acetyl-sulfamethoxazole (Human) metabolite of sulfamethoxazole 50
Ritonavir Antiviral 3.5
Sulfamethoxazole Sulfonamide antibacterial 20
Trimethoprim Antibacterial 60
a Excretion rates from Swiss Compendium of Medicines by Documed: www.compend
b Predicted minimum and maximum concentrations in urine calculated based on con
c Minimum and maximum predicted environmental concentrations in soil (PECsoil) ca
fertilizer for agriculture; see Supporting information.
d ND ¼ Not Determined.evaluated in this study, such as those recommended for public
sector ARV treatment in South Africa (WHO, 2005), may also be
present in the urine from eThekwini.
One consequence of the increased prescription and consump-
tion of antibiotics is the increased prevalence of antibiotic resis-
tance determinants. For example, a diversity of multidrug resistant
diarrheal bacteria, notably including Shigella spp., were isolated
from household water stored for use by HIV-positive patients in
Limpopo province (Samie et al., 2012). In the present study, the
sulfonamide antibiotic resistance gene, sul1, was detected in 100%
of urine samples. While the sul1 resistance gene is known to be
widespread in the environment (e.g., (Czekalski et al., 2014)) and is
not broadly representative of other antibiotic resistance de-
terminants, it is typically detected at lower rates in urine samples
than observed in the present study. For example, in a 16-country
study of urine collected from patients with urinary tract infections,
sul1 was detected in 31% of 350 uropathogenic E. coli isolates (as
compared to the sulfonamide resistance gene sul2 in 48% of iso-
lates). Co-trimoxazole is a common prescription for this infection
(Blahna et al., 2006). Further, the concentration of sul1 gene copies
was high, from 108 to 1010 gc/ml, compared to less than 107 gc/ml in
hospital and municipal wastewater efﬂuents evaluated in
Switzerland (Czekalski et al., 2012), while heterotrophic bacteria
concentrations were similar (~106 CFU/ml) in the source-separated
urine to the levels in wastewater evaluated by Czekalski et al.
(2012). The ubiquitous detection of sul1 in the present study thus
encourages further evaluation of the prevalence and health risks
associated with other clinically relevant ARGs in source-separated
urine, and especially those harbored within human pathogens.
Despite the potential health challenges from the spread of antibi-
otic resistance, HIV-infected African adults receiving co-
trimoxazole currently still garner consistent beneﬁts in survival
even in areas where co-trimoxazole resistance is common
(Zachariah et al., 2007).
Beyond the human health concerns associated with antibiotic
resistance determinants, pharmaceutical usage and environmental
release pose potential ecotoxicological risks. Urine discharged from
UDDTs or urine collected and applied directly as fertilizer may
contribute to such risks. However, recommendations regarding
environmentally safe concentrations of pharmaceuticals are
limited, especially for soil applications of human-waste derived
fertilizers (e.g., wastewater sludge, manure, or urine). Predicted noand predicted environmental concentrations in soil following a single application of
etion
[%]a
Predicted concentration
in urine (mg/L)b
Measured concentration
in urine (mg/L)
(avg ± 95% CI; n ¼ 20)
PECsoil (mg/kg)c
min max min max
1 e <2.5 0 0.3
74 246 31 ± 33 0 7.5
ND ND 98 ± 110 0 25
99 137 17 ± 29 0 5.4
2 e <1 0 0.1
0.7 25 30 ± 10 0.2 4.7
20 e 101 ± 97 0 23
526 1118 42 ± 18 0.2 7.1
303 468 360 ± 340 0.2 82
0.9 2.1 1.6 ± 0.5 0 0.2
121 187 2300 ± 1000 11 390
2 120 190 ± 140 0.4 39
ium.ch, last accessed March 10, 2015.
sumption in four countries (CH, DE, FR, USA); see Supporting information Table S4.
lculated based on measured urine concentrations for a single application of urine as
1 Durban Yearly Weather Summary: http://www.worldweatheronline.com/
Durban-weather-averages/Kwazulu-Natal/ZA.aspx, accessed January 28, 2014.
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for SMX, TMP, and diclofenac using aquatic PNECs and compound
physiochemical properties (Martín et al., 2012). For comparison to
these values, we estimated a range of predicted environmental
concentrations (PECsoil) and risk quotients (RQ ¼ PECsoil/PNECsoil)
based on urine application as fertilizer in agriculture (Table 3 and
Table S5). The estimated soil concentrations were based on a one-
time direct urine application to achieve 150 kg N/ha (see SI for
calculation), assuming no degradation of the target compound in
the soil. While the RQs for TMP and diclofenac (RQ<<1) indicated
no signiﬁcant environmental risk, the RQ for SMX for a range of
scenarios evaluated (RQ > 1) suggests a potential ecotoxicological
risk from this compound due to its high concentration in urine and
relatively low PNECsoil. The actual SMX concentration in soil, and
associated risk quotients, would depend on urine and water
application rates, the soil characteristics, the degradation of SMX in
soil, and measured PNECsoil values. However, the results presented
herein suggest that further detailed study on SMX ecotoxicity in
these scenarios is warranted.
The breadth, high frequency and sometimes high concentra-
tions of pharmaceuticals detected in source-separated urine in this
study highlight the importance of evaluating pharmaceutical fate
during urine collection and fertilizer production. Sequestering
these compounds via urine diversion and collection prevents their
release into the environment and provides an opportunity to
remove or transform the compounds via urine treatment.
4.3. Fate of pathogens and pharmaceuticals in treatment processes
for urine-derived fertilizer production
Due to the widespread detection of pathogenic viruses and
bacteria as well as high concentrations of several pharmaceuticals
in source-separated urine in eThekwini, thorough consideration of
the downstream urine treatment processes is imperative for the
protection of individuals handling stored urine and for its use as an
agricultural fertilizer. In eThekwini, the primary urine treatment
and fertilizer production technologies under development for po-
tential scale up are: (1) urine storage for pathogen inactivation; (2)
struvite fertilizer production for phosphorus recovery; and (3)
urine nitriﬁcation for ammonia stabilization followed by distilla-
tion to recover all nutrients in a concentrated liquid product (Udert
et al., 2015). In each of these technologies, processes promoting the
degradation, inactivation, or removal of pathogens and TrOCs may
occur. Below, available data from literature is interpreted in the
context of eThekwini to evaluate the treatment beneﬁts of nutrient
recovery processes in reducing environmental loads of human and
environmental health risk determinants from the application of
source-separated urine, or fertilizers produced from that urine, at
scale.
4.3.1. Urine storage
The efﬁciency of pathogen indicator organism inactivation
during the storage of urine under a range of conditions has been
extensively evaluated (H€oglund et al., 2002a; Nordin et al., 2013;
Vinneras et al., 2008). Uncharged ammonia (NH3), a volatile com-
pound produced during biological urea hydrolysis, acts as an in situ
sanitizer in stored urine (Decrey et al., 2015; Vinneras et al., 2008).
Measured ammonia concentrations in this study were similar to
those reported in urine storage tanks in Sweden (H€oglund et al.,
2000). To maximize its biocidal effect, NH3 losses from stored
urine should be minimized. Therefore, dilution of urine or the use
of unsealed tanks or aeration during pumping of urine to transport
facilities, which could lead to NH3 volatilization, should be limited.
Ammonia losses should also be avoided to limit occupational
inhalation or dermal exposure to ammonia, by which deleterioushealth effects may be experienced (ATSDR, 2004), as well as po-
tential detrimental environmental effects (Galloway and Cowling,
2002).
Besides NH3, high storage temperature is conducive to pathogen
inactivation in urine. Measured urine tank temperatures depend on
the external temperature, sun exposure, tank color, and time of day
that samples were taken. Fluctuating temperatures within urine
storage tanks due to diurnal heating from the sun may further
enhance inactivation (Nordin et al., 2013). Durban is characterized
by a mild subtropical climate, with average maximum tempera-
tures of 28 or 29 C occurring between January andMarch and 23 or
24 C in winters from June to August.1 Given these high tempera-
tures year-round, urine storage in Durban may achieve signiﬁcant
inactivation of a range of important pathogens. Speciﬁcally, of the
most frequently detected bacteria in the present study, the gram
negative bacteria Aeromonas spp. and Shigella spp. are expected to
be inactivated rapidly in undiluted, stored urinewith a temperature
above 20 C. A. hydrophila, for example, loses greater than 90% of
infectivity per day in urine at 20 C (H€oglund et al., 1998). This is
commonly observed for other gram negative bacterial pathogens
and fecal indicator organisms. C. perfringens, in contrast, is likely to
remain infective in stored urine for extended periods of time
(H€oglund and Stenstr€om, 1999).
Viruses in stored urine exhibit a wide range of inactivation rates
that are typically slower than those of gram negative bacteria. As
discussed above, dsDNA viruses are the most persistent in urine at
urine storage temperatures expected in Durban (Decrey, 2015). The
dsDNA viruses most frequently detected in this study, JCPyV and
HAdV, are thus likely to remain infective in undiluted or diluted
stored urine for several weeks or longer. In contrast, ssRNA viruses
such as HAV and NoV are expected to inactivate more rapidly than
dsRNA or dsDNA viruses due to susceptibility of the genome to
degradation.
While the efﬁciency of pathogen and surrogate inactivation
during the storage of urine under a range of conditions has been
extensively evaluated, data is lacking regarding the behavior of
pharmaceuticals during urine storage. Forthcoming results (€Ozel
Duygan et al., 2015) indicate little beneﬁt of urine storage for the
transformation of pharmaceuticals detected in eThekwini, as 11 out
of 12 compounds were very stable; only hydrochlorothiazide was
degraded substantially. Nevertheless, source-separation coupled
with urine collection has the potential to sequester excreted drugs
and reduce the diffuse discharge of pharmaceuticals to the
environment.
4.3.2. Struvite fertilizer production and drying
Struvite (MgNH4PO4$6H2O) can be precipitated from stored
urine by adding a magnesium source such as MgO, MgCl2 or bittern
(Etter et al., 2011). The process is completed by ﬁltration and drying
of the struvite precipitate, which can be applied directly as a
fertilizer.
In the production of struvite, heterotrophic bacteria in urine
accumulate in the solid during struvite precipitation and ﬁltration
and are inactivated during dryingwith decreasing struvitemoisture
content (Schoger, 2011). However, concentrations of the in situ
bacteria in struvitemay stabilize undermild drying conditions (e.g.,
20 C, 80% relative humidity). The inactivation kinetics of patho-
genic bacteria during struvite drying has not been considered spe-
ciﬁcally, though achieving only partial inactivation could be
problematic for attaining high fertilizer end-product quality.
Increased desiccation of struvite at elevated temperatures would
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above 55 C due to ammonia loss (Bhuiyan et al., 2008). Thorough
dessication of struvite at temperatures above ambient conditions is
also important to inactivate more resistant pathogens (e.g., hel-
minths), which are also retained in the precipitate during ﬁltration
(Decrey et al., 2011). In contrast to bacteria, viruses present in the
urine are retained in struvite pore spaces but are not preferentially
accumulated (Decrey et al., 2011). Virus inactivationwas also found
to increase linearlywithdecreasingmoisture contentof the struvite.
Similar to viruses, pharmaceuticals in struvite were contained in
the residual urine before struvite drying. For seven pharmaceuticals
evaluated, an average of 98% of the analytes remained in urine
following struvite precipitation (Ronteltap et al., 2007). Washing
struvite with water prior to drying was found to further reduce
pharmaceutical concentrations in the end-product by removing the
residual urine. Such a procedure would likely reduce pathogen
concentrations in struvite as well.
With proper washing and drying procedures, the production of
struvite can thus promote the inactivation or removal of bacterial
and viral pathogens in fertilizers produced from source-separated
urine and reduce end-product pharmaceutical concentrations.
These procedures facilitate the production of urine-based fertilizers
with shortened urine storage times. However, pathogens and
pharmaceuticals remaining in the urine after struvite precipitation
are not treated during this procedure and remain a potential hu-
man and environmental health hazard. Longer-term ﬁeld scale
assessments as well as analysis of additional pathogens and TrOC
targets are also required in order to fully assess the fate and
transport of contaminants during struvite production.
4.3.3. Urine nitriﬁcation for nutrient stabilization
An alternative to struvite production for urine nutrient recovery
is the application of biological nitriﬁcation to stabilize nutrients in
urine (Udert et al., 2003). Recent evaluation of the inactivation of
bacterial and viral surrogates during urine nitriﬁcation indicates
that nitriﬁcation is insufﬁcient as a stand-alone technology for
pathogen inactivation (Bischel et al., 2015). A relatively short
nitriﬁcation reactor hydraulic retention time would likely yield
only 90% or less inactivation. Viruses are likely to remain infective
through nitriﬁcation treatment. However, because volatile
ammonia is converted to nitrate during nitriﬁcation, the nitriﬁed
urine product can be distilled to yield a concentrated fertilizer and a
pathogen treatment beneﬁt. In a pilot reactor (Udert et al., 2015),
nitriﬁed urine is distilled for several hours at 80 C. This is a harsher
treatment than recommended for sanitization of compost (70 C for
30 min; US EPA, 2003), and can be expected to yield a microbially
safe product.
Of the 12 pharmaceuticals studied herein, only four were found
to degrade substantially during urine nitriﬁcation (€Ozel Duygan
et al., 2015). This is in accordance to the behavior of pharmaceuti-
cals in municipal wastewater treatment, as many are still detected
in considerable concentrations after wastewater treatment
(Michael et al., 2013).
Nitriﬁcation of urine alone thus does not provide a signiﬁcant
treatment beneﬁt for pathogens and pharmaceuticals in urine.
However, coupling biological nutrient stabilization with the post-
nitriﬁcation steps of distillation and advanced treatment can
improve the quality of the liquid fertilizer by inactivating patho-
gens and removing pharmaceuticals, respectively. Several treat-
ment processes have been successfully tested for the removal of
pharmaceuticals from stored urine: ozonation (Dodd et al., 2008),
electrodialysis (Pronk et al., 2006a), and nanoﬁltration (Pronk et al.,
2006b). Treatment with activated carbon was shown to be an
effective process for pharmaceutical removal from nitriﬁed urine
(€Ozel Duygan et al., 2015). Nitriﬁcation with distillation providesthe added beneﬁt over struvite production of complete nutrient
recovery for enhanced fertilizer product quality.
4.4. Conclusion
UDDTs provide increased access to sanitation, especially when
coupled with resource recovery and reuse, which further creates a
ﬁnancial driver for the sanitation system (Diener et al., 2014). With
a large network of dry, urine-diverting toilets in place, the oppor-
tunity is ripe in eThekwini tomove up the “sanitation ladder” (Mara
et al., 2010) by eliminating the practice of urine discharge via soak-
away pits. The presence of pathogens, pharmaceuticals and anti-
biotic resistance determinants in the source-separated urine re-
veals an important opportunity to reduce discharge of these
contaminants to the environment via urine collection. However,
the implications of such human and environmental health hazards
also require further evaluation. In particular, the results may be
contextualized in eThekwini via a quantitative microbial risk
assessment of local urine collection practices, when infective
pathogen concentrations are expected to be highest and opportu-
nities for accidental human-urine contact are likely greatest.
Beyond urine collection, urine nutrient recovery processes must
also yield high-quality products that are protective of human and
environmental health and that ensure adequate fertilizer quality
for optimal market value. The high content of such unwanted
substances in the fertilizer source material may impact the quality,
or perceived quality, of end-products. Therefore, this study also
highlights how potential environmental and human health con-
cerns could be reduced by incorporating a urine treatment step.
Processes to produce urine-derived fertilizers can be designed or
modiﬁed to inactivate pathogens and transform or remove phar-
maceuticals in source-separated urine. The production of the solid
fertilizer, struvite, can inactivate pathogens and remove pharma-
ceuticals from the end-product when implemented with proper
washing and drying procedures. Biological nitriﬁcation for urine
nutrient stabilization can be coupled with the post-nitriﬁcation
steps of distillation and advanced treatment to improve the qual-
ity of the liquid fertilizer in terms of pathogen and pharmaceutical
concentrations.
Further evaluation and optimization of such urine treatment
and fertilizer production technologies at ﬁeld-scales is needed to
reduce occupational hazards to staff involved in urine processing
and minimize environmental risks associated with urine manage-
ment. Nevertheless the prevention of pathogen and pharmaceutical
discharge to the environment via urine source separation and
collection is a considerable advantage to this sanitation technology.
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